Overview

Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of SYR-472, once daily (QD), in subjects with type 2 diabetes mellitus who have not achieved glycemic control with diet and exercise, or by taking metformin.
Phase:
Phase 2
Details
Lead Sponsor:
Takeda
Treatments:
Metformin
Sitagliptin Phosphate